These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1238 related articles for article (PubMed ID: 27509025)
1. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma. Lan XW; Zou XB; Xiao Y; Tang J; OuYang PY; Su Z; Xie FY PLoS One; 2016; 11(8):e0160758. PubMed ID: 27509025 [TBL] [Abstract][Full Text] [Related]
2. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study. Wei Z; Zhang Z; Luo J; Li N; Peng X J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162 [TBL] [Abstract][Full Text] [Related]
3. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era. Li PJ; Mo HY; Luo DH; Hu WH; Jin T Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326 [TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial. Yang H; Chen X; Lin S; Rong J; Yang M; Wen Q; Shang C; He L; Ren P; Xu S; Zhang J; Liu Q; Pang H; Shi X; Fan J; Sun X; Ma D; Tan B; Zhang T; Zhang L; Hu D; Du X; Zhang Y; Wen S; Zhang X; Wu J Radiother Oncol; 2018 Jan; 126(1):37-42. PubMed ID: 28864073 [TBL] [Abstract][Full Text] [Related]
5. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study. Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907 [TBL] [Abstract][Full Text] [Related]
6. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials. Kong L; Zhang Y; Hu C; Guo Y; Lu JJ Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641 [TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study. Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148 [TBL] [Abstract][Full Text] [Related]
8. Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era. Zhang LN; Gao YH; Lan XW; Tang J; Su Z; Ma J; Deng W; OuYang PY; Xie FY Oncotarget; 2015 Dec; 6(41):44019-29. PubMed ID: 26528755 [TBL] [Abstract][Full Text] [Related]
9. Posterior cervical lymph node metastasis as the valuable prognostic factor for stage IVA/IVB nasopharyngeal carcinoma treated with induction chemotherapy followed by concurrent chemo-radiotherapy. Thephamongkhol K; Setakornnukul J; Rojwatkarnjana S; Chansilpa Y Int J Biol Markers; 2014 Dec; 29(4):e387-94. PubMed ID: 25198554 [TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study. Su Z; Mao YP; Tang J; Lan XW; OuYang PY; Xie FY Tumour Biol; 2016 Apr; 37(4):4429-38. PubMed ID: 26499947 [TBL] [Abstract][Full Text] [Related]
11. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study. Li Y; Chen QY; Tang LQ; Liu LT; Guo SS; Guo L; Mo HY; Chen MY; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Shao JY; Sun Y; Tan J; Chen S; Ma J; Zhao C; Mai HQ BMC Cancer; 2017 Aug; 17(1):567. PubMed ID: 28836950 [TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study. Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538 [TBL] [Abstract][Full Text] [Related]
13. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost. Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757 [TBL] [Abstract][Full Text] [Related]
14. Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma. Liao K; Tao HY; Zhan ZJ; Qiu WZ; Zheng RH Oncol Res Treat; 2021; 44(11):602-612. PubMed ID: 34601467 [TBL] [Abstract][Full Text] [Related]
15. Non-metastatic stage IV nasopharyngeal carcinoma patients: analysis of the pattern of relapse and survival. Ozyar E; Gurkaynak M; Yildiz F; Atahan IL Radiother Oncol; 2004 Jul; 72(1):71-7. PubMed ID: 15236877 [TBL] [Abstract][Full Text] [Related]
16. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209 [TBL] [Abstract][Full Text] [Related]
17. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma. Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309 [TBL] [Abstract][Full Text] [Related]
18. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. Chen QY; Wen YF; Guo L; Liu H; Huang PY; Mo HY; Li NW; Xiang YQ; Luo DH; Qiu F; Sun R; Deng MQ; Chen MY; Hua YJ; Guo X; Cao KJ; Hong MH; Qian CN; Mai HQ J Natl Cancer Inst; 2011 Dec; 103(23):1761-70. PubMed ID: 22056739 [TBL] [Abstract][Full Text] [Related]
19. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial. Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190 [TBL] [Abstract][Full Text] [Related]
20. Advanced-Stage Nasopharyngeal Carcinoma: Restaging System after Neoadjuvant Chemotherapy on the Basis of MR Imaging Determines Survival. Liu LT; Chen QY; Tang LQ; Zhang L; Guo SS; Xie CM; Liu XW; Guo L; Mo HY; Chen MY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ Radiology; 2017 Jan; 282(1):171-181. PubMed ID: 27479804 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]